Education
About Us
Working with TipRanks
Follow Us
Mesoblast Ltd (MESO)
NASDAQ:MESO
MESO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.78 - $22.00
Previous CloseN/A
Volume155.35K
Average Volume (3M)212.00K
Market Cap
$1.49B
Enterprise Value$6.60B
Total Cash (Recent Filing)$38.03M
Total Debt (Recent Filing)$126.11M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Aug 27, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding127,778,220
10 Day Avg. Volume192,378
30 Day Avg. Volume211,997
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)0.61
Price to Sales (P/S)0.00
P/FCF Ratio-4.59
Enterprise Value/Market Cap4.43
Enterprise Value/Revenue273.24
Enterprise Value/Gross Profit-292.32
Enterprise Value/Ebitda-30.44
Forecast
1Y Price Target
$30.00Price Target Upside146.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Mesoblast News
PremiumCompany Announcements
Mesoblast Updates Securities Status with ASX
PremiumCompany Announcements
Mesoblast Announces Director Securities Changes Following AGM Approval
Bulls Say, Bears Say
Bulls Say
Financial PositionMesoblast is funded well into 2026, potentially extending further depending on the launch trajectory of Ryoncil in pediatric steroid refractory acute graft vs. host disease.
Market OpportunityThe potential pricing for Ryoncil in excess of $1.5M for a full course supports a significant market opportunity, validating the view that the GvHD opportunity alone could support Mesoblast's current valuation.
Regulatory ApprovalRyoncil gains approval in the US for pediatric steroid refractory acute graft vs host disease, marking a significant milestone for Mesoblast and validating FDA's supportive stance on cell therapy.
Bears Say
Competitive AdvantageRyoncil's approval as the only drug for patients under 12 could provide a competitive advantage, especially in the 12-18 year-old segment where it overlaps with Jakafi.
Pipeline DevelopmentSignificant potential for Mesoblast in its late-stage pipeline, including heart failure (HF), with potentially two near-term filings, as well as the ongoing P3 in chronic lower back pain (CLBP).
Regulatory RiskFDA approval of Ryoncil represents a watershed moment for Mesoblast, leading to a reduction in revenue risk adjustment and an increase in the 12-month price target.
Ownership Overview
―
Insiders
0.01% Mutual Funds
0.51% Other Institutional Investors
99.01% Public Companies and Individual Investors
MESO FAQ
What was Mesoblast Ltd’s price range in the past 12 months?
Mesoblast Ltd lowest stock price was $5.78 and its highest was $22.00 in the past 12 months.
What is Mesoblast Ltd’s market cap?
Mesoblast Ltd’s market cap is $1.49B.
When is Mesoblast Ltd’s upcoming earnings report date?
Mesoblast Ltd’s upcoming earnings report date is Aug 27, 2025 which is in 74 days.
How were Mesoblast Ltd’s earnings last quarter?
Currently, no data Available
Is Mesoblast Ltd overvalued?
According to Wall Street analysts Mesoblast Ltd’s price is currently Undervalued.
Does Mesoblast Ltd pay dividends?
Mesoblast Ltd does not currently pay dividends.
What is Mesoblast Ltd’s EPS estimate?
Mesoblast Ltd’s EPS estimate is -0.31.
How many shares outstanding does Mesoblast Ltd have?
Mesoblast Ltd has 127,778,220 shares outstanding.
What happened to Mesoblast Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mesoblast Ltd?
Currently, no hedge funds are holding shares in MESO
Mesoblast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (146.71% Upside)
$30.00 (146.71% Upside)
Blogger Sentiment
Bullish
MESO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 12.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 13.3%
Last 30 Days ▼ 13.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
69.35%
12-Months-Change
Fundamentals
Return on Equity
-21.26%
Trailing 12-Months
Asset Growth
-2.53%
Trailing 12-Months
Company Description
Mesoblast Ltd
Mesoblast Limited is an Australian-based regenerative medicine company specializing in the development of innovative cellular therapies. Operating primarily in the biotechnology sector, Mesoblast focuses on developing and commercializing allogeneic cellular medicines to treat complex diseases that are resistant to conventional treatments. The company's core products are based on its proprietary Mesenchymal Precursor Cell (MPC) technology platform, which is aimed at addressing a wide range of inflammatory and immunologic conditions.
MESO Company Deck
MESO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with significant advancements including the FDA approval of RYONCIL, successful fundraising, and promising clinical trial results. However, the company faces some challenges such as non-cash balance sheet impacts and ongoing trial enrollments.Read More>Technical Analysis
Travere Therapeutics
―
Disc Medicine
―
Kymera Therapeutics
―
Immunocore Holdings
―
Vera Therapeutics
―